GERN - Geron - Stock Price & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US3741631036
Cancer, Treatment, Myelodysplastic, Syndromes, Myelofibrosis, Inhibitor
Geron Corporation is a biopharmaceutical company that specializes in developing and commercializing innovative treatments for myeloid hematologic malignancies, a group of life-threatening blood cancers. The company's primary focus is on creating therapies that can effectively target and combat these complex diseases.
At the forefront of Geron's pipeline is imetelstat, a telomerase inhibitor that has shown promising results in Phase 3 clinical trials. This novel drug works by inhibiting the uncontrolled growth of malignant stem and progenitor cells, which are a hallmark of myeloid hematologic malignancies. By targeting these cells, imetelstat has the potential to revolutionize the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis, two devastating conditions that currently have limited treatment options.
With a rich history dating back to 1990, Geron Corporation has established itself as a leader in the biopharmaceutical industry. Headquartered in Foster City, California, the company has built a reputation for its commitment to innovation, scientific excellence, and patient-centric approach. For more information about Geron Corporation and its mission to transform the lives of patients with myeloid hematologic malignancies, visit their website at https://www.geron.com.
Drawdown (Underwater) Chart
![Drawdown / Underwater Chart for GERN - Geron - Stock Price & Dividends](https://www.valueray.com/images/drawdown_chart/GERN.NASDAQ_drawdown.png)
Overall Trend and Yearly Seasonality
![Drawdown / Underwater Chart for GERN - Geron - Stock Price & Dividends](https://www.valueray.com/images/chart/GERN.NASDAQ_seasonality.png)
GERN Stock Overview
Market Cap in USD | 2,785m |
Sector | Healthcare |
Industry | Biotechnology |
GiC SubIndustry | Biotechnology |
TER | 0.00% |
IPO / Inception | 1996-06-30 |
GERN Stock Ratings
Growth 5y | 70.5 |
Fundamental | - |
Dividend | 0.00 |
Rel. Performance vs Sector | 8.01 |
Analysts | 4.57/5 |
Fair Price Momentum | 4.89 USD |
Fair Price DCF | - |
GERN Dividends
Dividend Yield 12m | 0.00% |
Yield on Cost 5y | 0.00% |
Dividends CAGR 5y | 0.00% |
Payout Consistency | 0.0% |
GERN Growth Ratios
Growth 12m | 73.47% |
Growth Correlation 12m | 85% |
Growth Correlation 3m | -27% |
CAGR 5y | 24.28% |
CAGR/Mean DD 5y | 0.99 |
Sharpe Ratio 12m | 0.60 |
Alpha vs SP500 12m | 52.78 |
Beta vs SP500 5y weekly | 0.87 |
ValueRay RSI | 13.94 |
Volatility GJR Garch 1y | 67.83% |
Price / SMA 50 | -6.8% |
Price / SMA 200 | 29.18% |
Current Volume | 5764.3k |
Average Volume 20d | 7510k |
External Links for GERN Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of September 08, 2024, the stock is trading at USD 4.25 with a total of 5,764,280 shares traded.
Over the past week, the price has changed by -10.53%, over one month by -7.61%, over three months by +9.25% and over the past year by +81.62%.
According to ValueRays Forecast Model, GERN Geron will be worth about 5.4 in September 2025. The stock is currently trading at 4.25. This means that the stock has a potential upside of +27.53%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 7.4 | 73.2 |
Analysts Target Price | 4.8 | 13.6 |
ValueRay Target Price | 5.4 | 27.5 |